A cost-effectiveness approach to drug subsidy and pricing in Australia

Donald J. Birkett; Andrew S. Mitchell; Peter McManus

doi:10.1377/hlthaff.20.3.104

A cost-effectiveness approach to drug subsidy and pricing in Australia

Donald J. Birkett, Andrew S. Mitchell, Peter McManus

Research output: Contribution to journal › Article › peer-review

63 Citations (Scopus)

Abstract

The Australian government offers its citizens subsidies on a select list of pharmaceuticals. For a drug to qualify for inclusion on this list, its manufacturer must demonstrate that the drug is both clinically effective and cost-effective. In part, this measure, along with others, was introduced to improve clinical and economic outcomes. Although this evidence-based system has provided transparency and consistency in decision making about which drugs will be covered, it may not have contained the rate of increase in drug costs.

Original language	English
Pages (from-to)	104-114
Number of pages	11
Journal	Health Affairs
Volume	20
Issue number	3
DOIs	https://doi.org/10.1377/hlthaff.20.3.104
Publication status	Published - May 2001

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1377/hlthaff.20.3.104Licence: In Copyright

Cite this

@article{1bd3297102924d15807df99e2fee6226,

title = "A cost-effectiveness approach to drug subsidy and pricing in Australia",

abstract = "The Australian government offers its citizens subsidies on a select list of pharmaceuticals. For a drug to qualify for inclusion on this list, its manufacturer must demonstrate that the drug is both clinically effective and cost-effective. In part, this measure, along with others, was introduced to improve clinical and economic outcomes. Although this evidence-based system has provided transparency and consistency in decision making about which drugs will be covered, it may not have contained the rate of increase in drug costs.",

author = "Birkett, {Donald J.} and Mitchell, {Andrew S.} and Peter McManus",

year = "2001",

month = may,

doi = "10.1377/hlthaff.20.3.104",

language = "English",

volume = "20",

pages = "104--114",

journal = "Health Affairs",

issn = "0278-2715",

publisher = "Project Hope",

number = "3",

}

TY - JOUR

T1 - A cost-effectiveness approach to drug subsidy and pricing in Australia

AU - Birkett, Donald J.

AU - Mitchell, Andrew S.

AU - McManus, Peter

PY - 2001/5

Y1 - 2001/5

N2 - The Australian government offers its citizens subsidies on a select list of pharmaceuticals. For a drug to qualify for inclusion on this list, its manufacturer must demonstrate that the drug is both clinically effective and cost-effective. In part, this measure, along with others, was introduced to improve clinical and economic outcomes. Although this evidence-based system has provided transparency and consistency in decision making about which drugs will be covered, it may not have contained the rate of increase in drug costs.

AB - The Australian government offers its citizens subsidies on a select list of pharmaceuticals. For a drug to qualify for inclusion on this list, its manufacturer must demonstrate that the drug is both clinically effective and cost-effective. In part, this measure, along with others, was introduced to improve clinical and economic outcomes. Although this evidence-based system has provided transparency and consistency in decision making about which drugs will be covered, it may not have contained the rate of increase in drug costs.

UR - http://www.scopus.com/inward/record.url?scp=0035351404&partnerID=8YFLogxK

U2 - 10.1377/hlthaff.20.3.104

DO - 10.1377/hlthaff.20.3.104

M3 - Article

C2 - 11585158

AN - SCOPUS:0035351404

SN - 0278-2715

VL - 20

SP - 104

EP - 114

JO - Health Affairs

JF - Health Affairs

IS - 3

ER -

A cost-effectiveness approach to drug subsidy and pricing in Australia

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this